Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma

Cancers(2021)10.3390/cancers13236136Source: DataRank Database

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma is a research paper published in Cancers (2021). On theSindex it has a DataRank of 0. It has been cited 39 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access39 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 4.33)OA: goldTopics (31)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Lijie Xing ORCID,Kenneth C. Anderson ORCID,Yu‐Tzu Tai ORCID,Shih‐Feng Cho ORCID

Live enrichment

PubMed:34885245 PMC:PMC8657018 OpenAlex:https://openalex.org/W4200262317

National Cancer Institute

Grant: P50 CA100707

National Cancer Institute

Grant: RO1 CA 207237

National Cancer Institute

Grant: P01CA155258

NCI NIH HHS

Grant: R01 CA207237

National Institutes of Health

Grant: 5P50CA100707-03

Specialized Program of Research Excellence in Myeloma

National Institutes of Health

Grant: 3P01CA155258-07S1

Integrative Oncogenomics of Multiple Myeloma (1 of 2)

FWCI

4.33

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/13/23/6136/pdf?version=1638780877

publisherhttps://www.mdpi.com/2072-6694/13/23/6136/pdf?version=1638780877

publisherhttps://www.mdpi.com/2072-6694/13/23/6136/pdf

journalhttps://doi.org/10.3390/cancers13236136

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34885245

Fields of Study

Multiple Myeloma Research and TreatmentsCAR-T cell therapy researchSynthesis and Biological Evaluation0301 basic medicine03 medical and health sciences

Keywords

Chimeric antigen receptorDaratumumabAntigenImmunotherapyMedicineCancer researchMonoclonal antibodyImmunologyImmune systemAntibodyMultiple myelomaMMBCMACD38Immunomodulatory DrugsImidsB Cell Maturation AntigenMoabSlamf7Fcrh5Gprc5dOrphan G Protein-Coupled Receptor Class C Group 5 Member DSignaling Lymphocyte Activation Molecule Family 7Tumor Target AntigenBone Marrow (Bm) MicroenvironmentReview

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being